Clinical trial
Standard High-Dose Alpha Interferon Versus Intermittent High-Dose Alpha…
NCT00226408 · Dermatologic Cooperative Oncology Group, Other · Unknown status
Key facts
| NCT number | NCT00226408 |
|---|---|
| Title | Standard High-Dose Alpha Interferon Versus Intermittent High-Dose Alpha Interferon |
| Official title | Randomized, Multicenter Study for Adjuvant Treatment of Stage III Malignant Melanoma: Intermittent, High-Dose Intravenous Interferon Alpha-2b Versus Standard High-Dose Interferon Alpha-2b Therapy |
| Lead sponsor | Dermatologic Cooperative Oncology Group, Other |
| Status | Unknown status |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | Adjuvant, Stage III Malignant Melanoma, Interferon Alpha, Therapy |
| Intervention type | Drug |
| Interventions | Interferon-alpha-2b |
| Enrollment | 600 |
| Start date | Nov 1, 2003 |
| Completion | Sep 1, 2005 |
| First posted | Sep 27, 2005 |
| Last update posted | Jun 21, 2006 |
| Countries | Germany |
At a glance
- 10–99 Study sites
- No Results posted
- 1–9 FDA inspections linked to this trial
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: